This argument does not at all reflect the actual revenue model of pharmaceutical companies here in the US. In the private sector, far larger amounts of funding

This argument does not at all reflect the actual revenue model of pharmaceutical companies here in the US. In the private sector, far larger amounts of funding are spent on marketing than research[1]. The basic maths shows: investment in research can be maintained or even increased while providing greater access to the fruits of that research. The money is there. What we lack is the proper incentivisation. 1. https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-pharmaceutical-companies-are-spending-far-more-on-marketing-than-research/?utm_term=.1b16b33608f6 https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-p...